Clinical importance of clofibrate induced increase of creatine kinase catalytic activity concentration in serum.
Increases in serum catalytic activity concentrations as a side effect of treatment with clofibrate have been reported in cases with the without acute muscular syndromes. The prognostic value of the laboratory symptom without clinical signs remained contradictory. The conclusion of our experience in a long-term survey of patients with intermittent or consistently increased catalytic activity concentrations can be summarized in three points: 1. Increase in creatine kinase of skeletal muscular origin is a side effect of clofibrate to be seen not infrequently. 2. No muscular disease developed within observation times of more than 5 years. 3. The muscular syndrome described by Langer & Levy ((1968) N. Engl. J. Med. 279, 856--858) is a comparatively rare condition.
D002994:Clofibrate / Q000009:adverse effects* / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced*
D003402:Creatine Kinase; D002994:Clofibrate